Oncology Central

Is in vitro-acquired resistance to enzalutamide a useful model?


Prostate cancer is a major health concern among men worldwide, with an estimated 234,460 new cases diagnosed and 27,350 deaths in the USA alone in 2006 [1]. Significant advancements have been achieved in the fight against this deadly disease, both in terms of secondary prevention [2] and in the management of advanced prostate cancer resistant to castration [3], namely, castration-resistant prostate cancer (CRPC).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.